Thymidine phosphorylase (TP) is a key enzyme that contributes to the composition and decomposition of pyrimidine nucleotides. TP seems homologous to platelet-derived endothelial cell growth factor, and its effects on inducing vascularization and anti-apoptosis are closely related to growth and metastasis of colorectal carcinoma. In addition, TP is a key enzyme that catalyzes the transformation from 5-fluorouracil (FU) prodrugs of 5′-deoxy-5-fluorouridine (5′-DFUR) to 5-FU. The activity of TP is closely related to the sensitivity of colorectal carcinoma cells to fluorouracil drugs and targeted therapy. Given the important functions of TP in growth, metastasis, tumor treatment, and prognosis, determining its expression mechanism is significant. This article summarizes the research development of TP expression in colorectal carcinoma, tumor neovascularization, cytotoxicity activation of 5′-DFUR, and colorectal carcinoma therapy.
Introduction
Thymidine phosphorylase (TP) is a key enzyme that contributes in the metabolic process of pyrimidine nucleotides. TP has a structure similar to that of platelet-derived endothelial cell growth factor (PD-ECGF); therefore, these two constituents are considered to be the same substance. TP promotes angiogenesis and has important functions in growth, invasion, and metastasis of colorectal carcinoma 1 . TP also can selectively activate anticancer reagent 5′-deoxy-5-fluorouridine (5′-DFUR) into fluorouracil (5-FU), resulting in an inhibiting effect on cancer cells. Consequently, these drugs can have antitumor effects. Therefore, TP expression studies are important for investigating angiogenesis, invasion, and metastasis of colorectal carcinoma, as well as for chemotherapy.
Biological property of TP
Friedkin discovered TP in a biological body in 1954. In 1975, Voytek and Blank separated and purified TP from Escherichia coli and Salmonella, which had a 45 kDa subunit dimer. In 1978, Kubilus was the first to purify a eukaryotic cell TP from the amniotic membrane chorion of a human. This eukaryotic cell TP was a 47 kDa-subunit dimer that had the same properties as E. coli TP. In 1987, Miyazono stimulated an aortic endothelial cell and obtained PD-ECGF in platelet-cleaving factors from the proliferation of endothelial cells. In 1992, Furukawa discovered that the 120 amino acid sequences in the cDNA of E. coli TP were identical to the sequences of PD-ECGF through mass cloning experiments. This discovery has drawn attention to the relationship between TP and PD-ECGF. In 1993, Sumizawa's study showed that recombinant PD-ECGF possesses TP activity, and TP could promote angiogenesis activity. The PD-ECGF polypeptide could be recognized by anti-TP antibody. This result suggests that these two materials have a high degree of homology. In 1995, Miyadera purified human placenta TP and analyzed the amino acid sequences. He discovered that the N-terminal sequences of TP and PD-ECGF had slight differences, with some missed fragments in the course of purification. Therefore, TP and PD-ECGF were identified as transcription products from the same gene. To date, TP and PD-ECGF are considered similar substances that contribute in the metabolic process of pyrimidine nucleotides and promote angiogenesis inside the body.
TP is a homodimer that consists of two polypeptide chains. 
Relationship between TP and angiogenesis in colorectal cancer
Formation and development of malignant tumor generally rely on neovascularization. As an angiogenesis-promoting factor, TP has an important function in the growth, invasion, and metastasis of colorectal carcinoma. 
TP expression in colorectal carcinoma
The expression of TP in colorectal carcinoma tissues is apparently higher than in the surrounding normal tissues. 
Relationship between TP and colorectal carcinoma treatment
TP has a vital function in colorectal carcinoma treatment: it catalyzes the conversion from 5-FU prodrugs (e.g., 5′-DFUR and CAP) to 5-FU that has antitumor activity. Three sequential enzyme reactions are present in this process. CAP is converted to 5′-deoxidation-5-flucytosine (dFCyd) under the action of carboxy-esterase in the liver after intestinal absorption, after which it is converted to 5′-DFUR by cytidine deaminase in the tumor tissue. When 5′-DFUR enters the tumor tissue, it is converted into 5-FU that has antitumor activity by TP. 5-FU functions in targeted-antitumor effect by blocking the DNA synthesis of tumor cells 3 . Slager et al. 14 stated that TP is a target in oncotherapy processes with 5-FU and derivatives, and has an important function in growth, development, and metastasis processes of tumor. In 1998, Schwartz et al. 15 , transferred the INF gene into HT29 colorectal carcinoma cells, and found that the levels of TP proteins and mRNA increased. This laboratory finding indicated that INF could adjust TP expression during or after the transcription process. Thus, the conversion efficiency of 5′-DFUR to 5-FU increased, and the antitumor effects of 5′-DFUR were enhanced. In 2002, Nagata et al. 16 analyzed the colorectal cancer cells with human TP transfection using MTT and other methods. The results showed that TP activity obviously increased compared with non-transfected cancer cells in vitro and in vivo. The sensitivity to 5′-DFUR increased, and the antitumor effects were enhanced. This finding is also indicated in Boskos' study 17 . Research findings have shown that colorectal carcinoma cells hardly express TP. Although 5-FU prodrugs are effective in colorectal carcinoma treatment, the transfer mechanism of drugs in cancer tissue remains unclear. Current studies support that the interstitial cells of cancer tissues, especially TAM, have an important function in conversion processes. Zhang et al. 18 studied the antitumor effects of 5′-DFUR adjusted by two macrophage systems. The results showed that TP expressed by macrophage system transferred the 5′-DFUR to 5-FU, and consequently, 5-FU had an antineoplastic effect. This finding indirectly indicated that TP expression could strengthen the anticancer effect of 5′-DFUR . Zhang et al. 19, 20 analyzed the protein quantification and medium effective concentration on six colorectal carcinoma cell lines and two macrophage systems using ELISA, MTT, and other methods. The results showed that macrophages transferred 5′-DFUR to 5-FU; Thus, 5-FU could be released into the medium to produce a colorectal carcinoma cell growth-inhibiting effect. This result indicated that the macrophage could strengthen the antitumor effects of anticancer cells. Yasuno et al. 21 analyzed 97 colorectal carcinoma specimens through immunohistochemical staining method. The findings indicated that patients with high TP expression and treated with fluorouracil exhibited better prognosis. This result indirectly showed that TP expressed in the mesenchyme could strengthen the antitumor effects of 5′-DFUR. A number of chemotherapeutics, such as oxaliplatin, vorinostat, taxanes, and cyclophosphamide could improve TP expression in colorectal carcinoma cells. These drugs, together with fluorouracil, can produce a synergistic effect to improve the curative effect of chemotherapy. The study of Cassidy 22 showed that CAP applied with oxaliplatin could improve TP expression and chemosensitivity with a synergistic effect. Gennaro et al. 23 used RT-PCR, protein blot and immunohistochemical staining to prove that vorinostat with CAP could induce TP upregulation. This combined treatment also increased the collaborative anti-proliferation and cell apoptosis in vitro. 5-FU is a representative drug of colorectal carcinoma treatment that used to be the only therapeutic drug before 1985 24 . However, 5-Fu has significant toxic side effects, including diarrhea, nausea, vomiting, and myelosuppression. The development of biomedical technology resulted in the development of drugs with better therapeutic effects, such as CAP combined with oxaliplatin 22 . At present, 5-FU tends to be replaced by CAP as the best chemotherapeutic drug. On the other hand, CAP has some effects on patients who experienced 5-FU treatment failure. As an oral solution, CAP can simulate the antitumor effect of continuous intravenous drip of 5-FU. CAP is more convenient and simple to administer, prevents retention in vessels or chemotherapy pump, and has less side effects. Therefore, CAP is expected to be the drug of choice for the treatment of colorectal carcinoma 25 . Unger et al. 26 showed that CAP and celecoxib could be used with radiotherapy to obtain a good therapeutic effect. Chiorean et al. 27 
Summary
TP expression has dual influences on colorectal carcinoma. On one hand, excessive TP expression is related to infiltration, metastasis, and prognosis of colorectal carcinoma. Its promoting effect on angiogenesis based on enzymatic activity is also unique. On the other hand, TP is the key enzyme that contributes in the transformation from prodrug 5-FU to drugs with antitumor effects. TP also contributes in predicting toxicity of chemotherapy and sensitivity of colorectal cancer cells to 5-FU. TP is an effective target site which is the main focus for targeted therapy studies. However, further research is needed because many mechanisms of interactions between TP and other angiogenesis factors, as well as inhibiting factors, are still not clearly elucidated.
